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Abstract
 
Indoleamine 2,3-dioxygenase (IDO), an enzyme involved in the catabolism of tryptophan, is
expressed in certain cells and tissues, particularly in antigen-presenting cells of lymphoid organs
and in the placenta. It was shown that IDO prevents rejection of the fetus during pregnancy,
probably by inhibiting alloreactive T cells, and it was suggested that IDO-expression in anti-
gen-presenting cells may control autoreactive immune responses. Degradation of tryptophan,
an essential amino acid required for cell proliferation, was reported to be the mechanism of
IDO-induced T cell suppression. Because we wanted to study the action of IDO-expressing
dendritic cells (DCs) on allogeneic T cells, the human IDO gene was inserted into an adeno-
viral vector and expressed in DCs. Transgenic DCs decreased the concentration of tryptophan,
increased the concentration of kynurenine, the main tryptophan metabolite, and suppressed
allogeneic T cell proliferation in vitro. Kynurenine, 3-hydroxykynurenine, and 3-hydroxyan-
thranilic acid, but no other IDO-induced tryptophan metabolites, suppressed the T cell re-
sponse, the suppressive effects being additive. T cells, once stopped in their proliferation, could
not be restimulated. Inhibition of proliferation was likely due to T cell death because suppressive
tryptophan catabolites exerted a cytotoxic action on CD3
 
 
 
 cells. This action preferentially
affected activated T cells and increased gradually with exposure time. In addition to T cells, B
and natural killer (NK) cells were also killed, whereas DCs were not affected. Our findings
shed light on suppressive mechanisms mediated by DCs and provide an explanation for impor-
tant biological processes in which IDO activity apparently is increased, such as protection of
the fetus from rejection during pregnancy and possibly T cell death in HIV-infected patients.
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kynurenine
 
Introduction
 
Indoleamine 2,3-dioxygenase (IDO)
 
* 
 
is the rate-limiting
enzyme in the catabolism of tryptophan, expressed in a se-
ries of human and animal tissues, particularly in lymphoid
organs and placenta (1–3). Apart from low level expression
in healthy individuals, enzyme production markedly in-
creases during infection or inflammation and can be in-
duced by LPS, cytokines, or other agents (4–7). Low tryp-
tophan concentrations, which may be induced by IDO, are
associated with inhibited proliferation of viruses (8), proto-
zoan parasites (9, 10), and other pathogens (11) in eukary-
otic cells and also with decreased proliferation of tumor
cells (12, 13). Based on these observations it has been pos-
tulated that the role of IDO in vivo is to inhibit the propa-
gation of eukaryotic intracellular pathogens by depriving
them of tryptophan.
Recent studies support the idea that, in addition to de-
fense against pathogens, IDO participates in the regulation
of T cell responses (14). It was speculated that expression of
IDO in antigen presenting cells of the immune system may
control autoreactive T cells (14). Munn et al. demonstrated
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that IDO expression in the placenta is critically involved in
preventing rejection of allogeneic fetuses (15). It is well
known that, from an immunological viewpoint, pregnancy
constitutes a paradoxical situation in which a foreign tissue
is tolerated by the host. Munn et al. implanted time-release
capsules containing the IDO-inhibitor 1-methyl-trypto-
phan under the skin of pregnant mice and observed that
the fetus was rejected. Hints at a participation of T cells in
fetal rejection came from the same study, in which immuno-
deficient pregnant mice were reconstituted with T cells
specific for paternal MHC antigens inherited by the fetus
and thereafter treated with IDO inhibitor. Apparently, in-
hibition of IDO production in the placenta abrogated T
cell control and the pregnant mice lost their concepti.
Based on these observations, the authors proposed the fol-
lowing scenario: once the embryo implants and begins es-
tablishing connections with the mother’s blood supply, fe-
tal-derived cells located in the placenta start producing
IDO, a process supported by experimental findings (16).
The enzyme inhibits maternal T cells that otherwise would
make their way through the placenta and attack the fetus.
While it is clear that IDO suppresses the maternal T cell re-
sponse, the exact mechanism by which the enzyme protects
the allogeneic conceptus from maternal T cell attack has
not been elucidated. It is known that IDO catabolizes tryp-
tophan (2) and that tryptophan is an essential amino acid
(the rarest of the 20 amino acids in proteins) indispensable
for the biosynthesis of proteins. The in vitro studies of
Mellor et al. reveal that T cells are specifically sensitive to
tryptophan deprivation (3, 14). At low tryptophan concen-
trations, cell cycle progression was halted at a mid-G1 arrest
point (14). Restoration of tryptophan to arrested cells,
along with a second round of T cell receptor signaling, ab-
rogated the state of areactivity and induced further cell cy-
cle progression. These and other observations lead to the
hypothesis that the main mechanism by which IDO inhib-
its cell proliferation is the depletion of tryptophan.
In the current series of experiments, we constructed re-
combinant replication-defective adenoviruses harboring
the human IDO gene, expressed the gene in human DCs
and showed that such cells are capable of preventing prolif-
eration of allogeneic T cells in vitro. Thereafter, we ana-
lyzed the mechanism of inhibition and, in contrast to pre-
vious studies, obtained conclusive evidence for a mediation
of suppression by IDO-induced tryptophan metabolites.
 
Materials and Methods
 
Construction of Replication-defective Recombinant IDO-Adenovi-
ruses.
 
Replication-defective adenoviruses were generated by en-
coding cDNA for human IDO according to a method described
previously (17). The human IDO gene was inserted into a shuttle
plasmid (pAdTrack-CMV, harboring the green fluorescence pro-
tein gene, or pShuttle-CMV, without the GFP gene) (Q-Bio-
gene). The resultant plasmid was linearized by digestion with re-
striction endonuclease PmeI and subsequently cotransformed
with an adeno-5 virus backbone (pAdEasy-1) into 
 
Escherichia coli
 
cells BJ5183. Recombinants were selected for kanamycin resis-
tance, and recombination confirmed by restriction digest with
PacI. The relevant clones yielded a large fragment (near 30 kb),
plus a smaller fragment (3.0 or 4.5 kb). Finally, the linearized re-
combinant IDO plasmid was transfected by Effectene Transfec-
tion Reagent kit (QIAGEN) into adenovirus packaging cells
(911 cells 
 
 
 
 E1-transformed human embryonic retinoblast cell
line) at 50% confluency. In case of pAdTrack-based vectors,
transfection and viral production can be monitored by GFP ex-
pression. When a cytopathogenic effect becomes evident (usually
7–10 d after transfection), the cells are scraped off, repeatedly
dounced, and centrifuged. Part of the supernatant is used for fur-
ther multiplication of viruses. The viruses were purified via ultra-
centrifugation on CsCl-gradient, rebuffered in conservation
buffer, titrated, and kept at –80
 
 
 
C until use. Titration was per-
formed by limiting dilution of viral suspension on 911 cells. The
last “infective concentration” was determined by checking the
GFP expression, in case of pAdTrack-CMV constructs, or by
PCR with adenoviral-specific primers, in case of pShuttle-CMV
constructs. Two recombinant vectors were generated, IDO-
adeno-GFP (with the GFP gene) and IDO-adeno (without GFP).
The nucleotide IDO sequence of recombinant adenoviruses was
determined using the dideoxy termination method of Sanger. Se-
quence analysis was performed in an ABI-3077 sequencer (Ap-
plied Biosystems) and identity with the sequence of the gene
bank was ascertained. Transcription of the IDO gene in trans-
fected eukaryotic cells was verified by RT-PCR. In brief,
mRNA was extracted from IDO-adeno-infected 911 cells
(QuickPrep Micro mRNA Purification kit; Amersham Bio-
sciences Europe), transcribed with Moloney virus leukemia re-
verse transcriptase into cDNA (Ready-to-go-Primed First-Strand
kit; Amersham Biosciences Europe), and amplified by PCR with
IDO-specific primers. PCR products were analyzed by agarose
gel electrophoresis with ethidium bromide staining.
 
Generation of Human Dendritic Cells.
 
Dendritic cells (DCs) were
generated from CD14-positive blood monocytes as described
previously (18). In brief, peripheral blood mononuclear cells of an
HLA-typed healthy donor were separated by density gradient
centrifugation and CD14-positive monocytes were isolated by
adherence to culture dishes. Nonadherent cells were discarded.
After culture of monocytes in the presence of human rGM-CSF
(666 U/ml) and rIL-4 (1,000 U/ml) for 7 d, rTNF-
 
 
 
 (10 ng/ml)
was added for an additional 2 d to induce maturation of DCs.
Characterization of DC phenotype was performed by flow cy-
tometry using the following mouse mAbs: anti–CD14-FITC;
anti–HLA-DR-FITC; anti–CD1a-PE; anti–CD86-PE; and anti–
CD83-PE (BD Biosciences). DCs were kept in liquid nitrogen
until use.
 
Separation of Lymphocyte Subpopulations.
 
Cells were separated
by negative selection via magnetic beads. Lymphocytes (PBMCs)
were obtained from blood of healthy donors by density gradient
centrifugation, washed, and incubated at 
 
 
 
4
 
 
 
C for 10 min with
monoclonal mouse antibody mixes directed against lymphocyte
subpopulations (10
 
7
 
 cells plus 20 
 
 
 
M antibody mix). Thereafter,
the cells were washed and incubated at 
 
 
 
4
 
 
 
C, for 10 min with 50
 
 
 
l magnetic beads coated with Fc-specific antibodies (Dynabeads;
Dynal). Antibody-labeled cells were removed with a magnet. To
increase the purity of the remaining lymphocyte subpopulation,
the procedure was repeated with another portion of magnetic
beads. The purity of negatively selected cells was for 85–90% T
cells, 70–80% NK cells, and 90% B cells.
 
Cell Cultures.
 
(a) Allogeneic T cell proliferation. DCs were
infected with recombinant IDO-adeno-GFP (DC-IDO-GFP),
IDO-adeno (DC-IDO), or with control adenoviruses (DC- 
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adeno) at a multiplicity of infection (MOI) up to 500 for 2 d.
Lymphocytes (PBMCs) were separated from peripheral blood of
healthy donors by density gradient centrifugation and typed for
HLA antigens. Only HLA-DR-different responder lymphocytes
were used for DC-induced stimulation. Native DCs only, lym-
phocytes only, native DCs plus allogeneic lymphocytes, DC-
IDO-GFP plus allogeneic lymphoytes, DC-IDO plus allogeneic
lymphoytes, DC-adeno plus allogeneic lymphocytes (each time
10
 
5
 
 DC plus 10
 
5
 
 lymphocytes in 0.2 ml medium) were cultured in
RPMI 1640 medium (GIBCO BRL Life Technologies GmbH)
with 10% FCS (final tryptophan concentration 5.25 mg/l 
 
 
 
 25.69
 
 
 
M) and Penicillin G/Streptomycin. After 5 d, 
 
3
 
[H]thymidine
was added for 12 h and the number of counts (counts per min-
ute 
 
 
 
 cpm) determined in a 
 
 
 
-counter (Inotech Biosystems).
To verify whether IDO expression or adenovirus infection
harm the DCs, 10
 
5
 
 cells were infected with IDO-adeno-GFP,
IDO-adenovirus, or adenovirus only at a stepwise decreasing
MOI (500, 250, 125 ... 3.9) and cell viability was measured in
FACS
 
®
 
 after double staining with 7 amino actinomycin D (7-
AAD) and anti-CD83 antibody-PE. The percentage of dead cells
never exceeded 30% for any MOI after IDO-adeno-GFP- or
IDO-adeno-infection and 40% after adenovirus (control)-infec-
tion. Moreover, these values were not higher than native DCs
cultured for the same period of time. The experiment was re-
peated using ethidium bromide or Trypan’s blue staining with
virtually the same result. These findings show that neither IDO-
expression nor adenovirus infection harm DCs under the de-
scribed conditions.
 (b) CD3 stimulation of T cells. Peripheral blood lymphocytes
were cultured (10
 
5
 
 cells per well) in RPMI 1640 (10% FCS) with
anti-CD3 mAb (Ortho Diagnostic Systems, Inc.) (final dilution
1:200). After 2 d, cell proliferation was assessed by measuring
 
3
 
[H]thymidine incorporation (cpm) as described previously.
 (c) Tryptophan metabolite titration curves. Kynurenine,
3-hydroxykynurenine, anthranilic acid, 3-hydroxyanthranilic acid,
and quinolinic acid (Sigma-Aldrich) (for all substances purity
 
  
 
98%) were dissolved in RPMI 1640 and added to cell cultures at
various concentrations. In an other experiment, to determine
whether the metabolites have an additive effect, equal concentra-
tions of the compounds were mixed and added to the cultures.
After 2 d, 
 
3
 
[H]thymidine was added and the number of counts re-
corded. Positive controls consisted of CD3-stimulated cells with-
out metabolites and negative controls of unstimulated cells.
 (d) Restimulation of suppressed T cells. Lymphocytes (10
 
5
 
cells per well) were cultured in RPMI 1640 (10% FCS) with
anti-CD3 mAb (final dilution 1:200) and kynurenine (dilution
series). After 2 d the cells were washed, the cell culture medium
(RPMI 1640 plus 10% FCS) was replaced, and the cells were
stimulated with Concanavalin A (6.25 
 
 
 
g per well). After another
2 d, 
 
3
 
[H]thymidine was added and cpm determined. Controls
consisted of cells prestimulated with anti-CD3 but not pretreated
with kynurenine.
In an other restimulation experiment lymphocytes were stimu-
lated with allogeneic DCs as described previously, in the presence
(47–1,500 
 
 
 
M) or absence of kynurenine. Control cultures con-
tained DCs or lymphocytes only. After 5 d the cells were exten-
sively washed, and restimulated with an identical number of DCs
derived from the same donor or from third party donors.
 
3
 
[H]thymidine was added to all cultures and the number of
counts (cpm) determined.
 (e) Tryptophan titration curve. To define the concentration of
tryptophan which reduces lymphocyte proliferation in our test
system, 10
 
5
 
 lymphocytes were incubated in tryptophan-free
RPMI 1640 medium (GIBCO BRL Life Technologies) with or
without 10% FCS, stimulated with anti-CD3 mAb, and various
amounts (0–38 
 
 
 
M) of tryptophan were added. Unimpaired pro-
liferation was observed down to 0.30 
 
 
 
M (medium with FCS)
and 1.20 
 
 
 
M (without FCS). Complete inhibition was not ob-
tained at any concentration (positive control 100% proliferation;
maximal suppression in medium with FCS: 
 
 
 
66% and without
FCS: 
 
 
 
33%). All cell cultures were done in triplicate.
 
Determination of Tryptophan and Kynurenine Concentration in Cell
Cultures.
 
Native DCs (control), DC-IDO-GFP, DC-IDO, or
DC-adeno (control) were cultured under conditions described
above and tryptophan and kynurenine were measured at the end
of culture. 20 
 
 
 
l supernatant was collected and the tryptophan
concentration was defined using reversed-phase high pressure liq-
uid chromatography (RP18 Hypersil ODS column) (Supelco,
Inc.) and photometric detection (fluorescence at 278/363 nm). In
another test the cells were lysed, centrifuged, and the kynurenine
concentration was measured in the supernatant spectrophotomet-
rically (19). In brief, 75 
 
 
 
l supernatant was incubated with 125 
 
 
 
l
methylene blue reaction buffer for 1 h at 37
 
 
 
C, and the reaction
was stopped with 30% trichloroacetic acid. After centrifugation,
125 
 
 
 
l supernatant was incubated with 125 
 
 
 
l Ehrlich reagent for
10 min at room temperature in a microtiter plate. Optical density
was measured at 480 nm. The values were referred to a standard
curve with defined kynurenine (0–120 
 
 
 
M) concentrations.
 
Detection of Cell Death.
 
Lymphocytes were stimulated in cul-
ture with anti-CD3 mAbs (described above) in the presence or
absence (control) of 1,501 
 
 
 
M kynurenine, 510 
 
 
 
M 3-hydroxy-
anthranilic acid, 348 
 
 
 
M 3-hydroxykynurenine, or metabolite
mixture (64 
 
 
 
M kynurenine plus 64 
 
 
 
M 3-hydroxykynurenine
plus 64 
 
 
 
M anthranilic acid plus 64 
 
 
 
M 3-hydroxyanthranilic
acid plus 64 
 
 
 
M quinolinic acid). After 3 d the cells were washed
and resuspended in PBS (10
 
6
 
 cells/ml). Thereafter, the cells (100
 
 
 
l suspension) were labeled with anti-CD3-FITC antibody (3
 
 
 
l), stained with 5 
 
 
 
l 7-AAD for 15 min, and the percentage of
7-AAD-positive (dead) T cells was determined in a FACScan™.
In an other experiment T cells, B cells, NK cells, or DCs were
separated from PBMCs by magnetic beads or generated as de-
scribed and cultured (5 
 
 
 
 10
 
5
 
 cells/ml) with a mixture of
kynurenine metabolites (kynurenine plus 3-hydroxykynurenine
plus anthranilic acid plus 3-hydroxyanthranilic acid plus quino-
linic acid) (8, 16, or 32 
 
 
 
M, respectively for each compound). In
one setting T cells were activated with anti-CD3 antibody. Cell
death was measured daily for 5 d by 7-AAD staining and ex-
pressed in percentage of dead cells.
 
Statistics.
 
All tests were performed in triplicate and results are
given as mean 
 
 
 
 SD. For calculating half-inhibitory (I
 
50
 
) concen-
trations of substances, the mean proliferation (cpm) of stimulated
and completely suppressed cells was determined. Thereafter, the
concentration of substance giving 50% proliferation was calcu-
lated by regression.
 
Results
 
IDO-Gene Expression in Human DCs.
 
Human IDO cDNA
was inserted into a shuttle vector and recombined with
an adeno-5 backbone vector in bacteria as described
previously (17, 20). The replication-defective recombi-
nant IDO adenoviruses were multiplied in 911 cells. Se-
quence analyses confirmed the correct sequence of human
IDO (unpublished data) and RT-PCR with IDO-specific
primers proved the transcription of IDO transgene in eu- 
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karyotic cells infected with recombinant adenoviruses
(Fig. 1).
DCs were generated from blood monocytes in the pres-
ence of GM-CSF and IL-4, maturation was induced by
TNF-
 
 
 
, and the phenotype was verified by FACS
 
®
 
 analysis
(18). These cells were infected with the recombinant IDO-
adenoviruses. The efficiency of infection was monitored by
expression of the green fluorescence marker protein har-
bored by the virus. Vital staining using FACS
 
®
 
 analysis
showed that DCs remained viable after adenoviral infec-
tion. It is known that IDO catalyzes the oxidation of tryp-
tophan, resulting in kynurenine and other metabolites (21–
23). To verify whether transgenic IDO exerted its catabolic
effect, tryptophan as well as kynurenine were measured in
cultures of DCs infected with IDO-adeno (Fig. 2, A and
B). As expected, the tryptophan concentration significantly
decreased while kynurenine increased.
 
IDO-expressing DCs Reduce Allogeneic T Cell Prolifera-
tion.
 
The next experiment addressed the question whether
IDO-expressing DCs inhibit the proliferation of HLA-
incompatible T cells. Native DCs or IDO-expressing
DCs were coincubated with allogeneic T cells and prolifer-
ation was determined by 
 
3
 
[H]thymidine incorporation. A
significant reduction of proliferation was noted by coincu-
bating T cells with IDO-DCs (Fig. 3), demonstrating the
inhibitory effect of IDO on allogeneic T cells.
 
Kynurenine Inhibits T Cell Proliferation.
 
Previous studies
came to the conclusion that tryptophan depletion is the
mechanism by which IDO inhibits T cell activation (3, 14).
An alternative mechanism would be that metabolites result-
ing from tryptophan breakdown influence T cell respon-
siveness. IDO-induced tryptophan degradation results in
kynurenine, 3-hydroxykynurenine, anthranilic acid,
3-hydroxyanthranilic acid, and quinolinic acid (21–23),
whereby kynurenine is the main product. Therefore, we
first tested the influence of kynurenine on the allogeneic T
cell response. As shown in Fig. 4 A, 
 
L
 
-kynurenine was able
to completely inhibit the proliferation of T cells stimulated
Figure 1. Transcription of IDO-gene in eukaryotic cells infected with
recombinant IDO-adenoviruses. mRNA was extracted from human em-
bryonic retinoblast cells infected with IDO-adeno-GFP, IDO-adeno, or
with replication-defective adenoviruses (neg. ctr.-a) and reverse tran-
scribed into cDNA. PCR with IDO-specific primers was performed and
the products analyzed by agarose gel electrophoresis. Positive control
consisted of material extracted from recombinant IDO-adenoviruses and
neg. ctr.-b of water instead of template. Lane 1: DNA molecular weight
marker; lane 2: pos. ctr., 3, neg. ctr.-b; lane: 4, IDO-adeno-GFP; lane 5:
IDO-adeno; lane 6: neg. ctr.-a; lane 7: DNA molecular weight marker.
Lanes 4 and 5 show the relevant IDO-specific bands.
Figure 2. Tryptophan and kynurenine concentration in cultures of
IDO-expressing DCs. Native DCs (control), DCs infected with IDO-
adeno-GFP, IDO-adeno, or native replication-defective adenoviruses
(control) were cultured in RPMI 1640 plus 10% FCS. Tryptophan (A)
and kynurenine (B) concentrations were determined and the values ( M/
105 cells) are shown on the ordinate.
Figure 3. Reduction of allogeneic T cell stimulation by IDO-express-
ing DCs. Native DCs (pos. ctr.), DCs infected with IDO-adeno-GFP,
IDO-adeno, or replication-defective adenoviruses (control) were coincu-
bated with allogeneic peripheral blood lymphocytes for 6 d and cell pro-
liferation measured by 3[H]thymidine incorporation (cpm) (ordinate).
Negative controls consisted of DCs or lymphocytes only.
Figure 4. Effect of kynurenine on T cell proliferation induced by allo-
geneic DCs or anti-CD3 antibody. Peripheral lymphocytes were stimu-
lated with (A) allogeneic DCs or (B) anti-CD3 mAb for 6 and 3 d, respec-
tively. Various amounts of kynurenine (abscissa) were added to the
cultures. Positive control was performed without kynurenine. T cell prolif-
eration was determined by 3[H]thymidine incorporation (cpm) (ordinate). 
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by allogeneic DCs (50% inhibition 
 
  
 
I
 
50
 
: 157 
 
 
 
M). More-
over, 
 
L
 
-kynurenine also suppressed proliferation of CD3-
stimulated T cells (I
 
50
 
: 553 
 
 
 
M) (Fig. 4 B). The same effect
was noted with 
 
D
 
-kynurenine (unpublished data).
 
Kynurenine-suppressed T Cells Cannot Be Restimulated.
 
In the experiment depicted in Fig. 5, A and B, T cells were
stimulated with anti-CD3 antibody in the presence of vari-
ous amounts of kynurenine, extensively washed, and re-
stimulated with Con-A in the absence of kynurenine. The
results show that kynurenine-suppressed T cells cannot be
restimulated.
In a second experiment we addressed the question
whether T cells stimulated with allogeneic DCs in the pres-
ence of kynurenine can be restimulated with donor-spe-
cific or third party DCs (Fig. 6). As expected, T cells di-
rected against a certain donor, once suppressed cannot be
restimulated with DCs from the same donor (Fig. 6, top
and bottom curve at 1,500, 751, and 375 
 
 
 
M). Third-party
DCs, however, are able to restimulate the T cells (medium
curve). The degree of restimulation by third-party donors
depends on the dose of kynurenine to which the cells were
exposed. At extremely high doses (1,500 or 750 
 
 
 
M) only
minimal reactions was noted, whereas at medium or low
doses (375–47 
 
 
 
M) significant restimulation takes place.
Most importantly, at any kynurenine concentration, third-
party restimulation (medium curve) was significantly higher
than donor-specific restimulation (bottom curve). This
finding suggests that kynurenine preferentially compro-
mises activated T cells. As we will see later (Fig. 10, A and
B), this was confirmed by further analyses.
 
Other Tryptophan Metabolites Also Suppress the T Cell Re-
sponse.
 
The question arose whether, in addition to
kynurenine, other tryptophan metabolites also inhibit T
cell proliferation. As shown in Fig. 7, A–D, 3-hydroxy-
kynurenine and 3-hydroxyanthranilic acid both suppress T
cells, whereas anthranilic and quinolinic acid were not sup-
pressive within the tested range of concentrations. In order
of their effectiveness, the T cell active components of tryp-
tophan catabolism were: 3-hydroxyanthranilic acid (I
 
50
 
: 96
 
 
 
M), 3-hydroxykynurenine (I
 
50 
 
  
 
187 
 
 
 
M), and kynure-
nine (I
 
50 
 
  
 
553 
 
 
 
M).
 
Tryptophan Metabolites Have an Additive Effect on T
Cells.
 
In vivo as well as in cell cultures, none of the tryp-
tophan metabolites acts as a single component but in the
presence of other metabolites. This prompted us to analyze
the effect of metabolite mixtures. Fig. 8 A shows the action
of kynurenine in combination with all other metabolites. It
is evident that much smaller concentrations of kynurenine
are required when combined with equal amounts of the
other compounds (in combination: I
 
50 
 
  
 
15 
 
 
 
M, as single
substance: I
 
50 
 
  
 
553 
 
 
 
M; Fig. 4 B). Even the combination
of three or two active components enhances the effect of
single substances (Fig. 8, B–D). For instance, whereas
kynurenine is effective at 553 
 
 
 
M (Fig. 4 B) and 3-hydroxy-
anthranilic acid at 96 
 
 M (Fig. 7 C) as single components,
when combined (Fig. 8 D), 21  M of each substance is suf-
ficient to induce the same effect. Other combinations
showed similar results, indicating that the metabolites add
or even potentiate their respective effects.
Kynurenine, 3-Hydroxykynurenine, 3-Hydroxyanthranilic
Acid, and the Metabolite Mixture Induce T Cell Death. The
lack of restimulation of kynurenine-suppressed T cells
might be attributable to either T cell areactivity or cell
death. To analyze the underlying mechanism, the cells
were stimulated as described in the presence of suppressive
amounts of kynurenine, 3-hydroxykynurenine, 3-hydroxy-
anthranilic acid, or a mixture of all metabolites for 3 d, and
cell viability was determined in FACS® by vital staining
with 7-AAD. As shown in Fig. 9, virtually all cells died at
suppressive concentrations of single components or the
metabolite mixture.
Tryptophan Metabolites Have a Time-dependent Cytotoxic
Effect. In contrast to cell cultures, the exposure of lym-
phocytes to kynurenine derivatives “in vivo” is long-last-
ing. If the cytotoxic effect increases with time, even small
Figure 5. Polyclonal restimulation of kynurenine-suppressed T cells.
Peripheral lymphocytes were stimulated with (A) anti-CD3 mAb in the
presence of various amounts of kynurenine (abscissa). Positive control
consisted of T cell stimulation in the absence of kynurenine. After 2 d the
cells were washed and (B) restimulated with Con-A for another 3 d. T
cell proliferation was determined by 3[H]thymidine incorporation (cpm)
(ordinate).
Figure 6. Allogeneic restimulation of T cells activated with allogeneic
DCs. Peripheral blood lymphocytes were stimulated with allogeneic DCs
in the presence of decreasing amounts of kynurenine (abscissa). After 5 d
the cells were extensively washed and restimulated with DCs from the
same or unrelated donors. T cell proliferation was measured by 3[H]thy-
midine incorporation (cpm) (ordinate) after primary and secondary stimu-
lation. The curves show the degree of proliferation after the first stimula-
tion (top curve) and upon restimulation with third-party (intermediate)
or donor-specific DCs (bottom curve).452 IDO-induced T Cell Suppression Is Mediated by Tryptophan Metabolites
amounts of metabolites may be effective. To test whether
cytotoxicity is time dependent, purified T cells were incu-
bated for 5 d with various amounts of tryptophan metabo-
lites and the percentage of dead cells was determined daily
(Fig. 10). The findings clearly show that the cytotoxic ef-
fect is time dependent and that even small amounts of sub-
stances become cytotoxic after an exposure time of several
days. As shown in Fig. 11, B and C, this is also the case for
B and NK cells.
Tryptophan Metabolites Preferentially Kill Activated T
Cells. An important question is whether activated T cells
are more susceptible to cell death than resting ones. Fig. 10,
A and B, shows the metabolites’ action on activated versus
nonactivated T cells. Evidently, activated cells are more
sensitive. For instance, whereas 16  M metabolite mixture
killed 60% activated T cells, it affected only 21% nonacti-
vated cells after 5 d of culture.
Tryptophan Metabolites Act on Several Lymphocyte Subpopu-
lations. In the experiment depicted in Fig. 11, A–D, the
effect of tryptophan metabolites on lymphocyte subpopu-
lations was analyzed. T, B, and NK cells were separated
by magnetic beads from PBMCs and incubated for 5 d
with various amounts of metabolite mixture. The results
show that all three subpopulations are sensitive to these
compounds. Interestingly, DCs, the cells which produce
the IDO and thus generate kynurenine, are resistant to
cell death. This is in line with our observations showing
that IDO-adenovirus-transfected DCs are not harmed
more than mock-transfected or untreated cells (Materials
and Methods).
Discussion
In their study, Moffett et al. attempted to detect IDO ac-
tivity at the single-cell level based on immunohistological
staining of quinolinic acid, which is the terminal metabolite
of the enzymatic pathway initiated by IDO (24). Their
findings indicated that IDO-producing cells are distributed
in lymphoid tissues and sporadically in other tissues, and
have a macrophage- or DC-like appearance (3, 24). Recent
evidence for expression of IDO in DCs came from the
work of Hwu et al. who induced IDO production in hu-
man DCs by stimulation with IFN-  and CD40 ligand
(25). Although it is generally known that DCs are potent
activators of T cells, they may also play a pivotal role in the
induction of peripheral tolerance (26). Because IDO is
known to reduce T cell proliferation, it is tempting to
speculate that IDO-expressing DCs have suppressive prop-
erties. In their studies, Hwu et al. (25) inhibited the prolif-
eration of OKT3-stimulated autologous T cells with IDO-
producing DCs. In another study, stimulation of CD8  
DCs with IFN- , which is known to promote IDO pro-
Figure 7. Effect of IDO-induced tryptophan metab-
olites on T cell proliferation. Peripheral lymphocytes
were stimulated with anti-CD3 antibody for 3 d in the
presence of various amounts (abscissa) of (A) 3-hydroxy-
kynurenine, (B) anthranilic acid, (C) 3-hydroxyan-
thranilic acid, or (D) quinolinic acid. Positive control
consisted of T cell stimulation in the absence of metab-
olites. T cell proliferation was determined by 3[H]thy-
midine incorporation (cpm) (ordinate).
Figure 8. Additive effect of tryptophan metabolites.
Peripheral lymphocytes were stimulated with anti-CD3
antibody for 3 d and decreasing amounts of (A)
kynurenine plus 3-hydroxykynurenine plus anthranilic
acid  plus 3-hydroxyanthranilic acid  plus quinolinic
acid, (B) kynurenine plus 3-hydroxykynurenine plus
3-hydroxyanthranilic acid, (C) kynurenine  plus
3-hydroxykynurenine, (D) kynurenine plus 3-hydroxy-
anthranilic acid were added. All components of a mix-
ture were added in equal amounts. The concentration
of single substances is shown (abscissa).453 Terness et al.
duction, enhanced their tolerogenic activity toward CD4 T
cells (27). These as well as similar findings obtained with
macrophages (14) fostered the hypothesis that expression of
IDO in antigen-presenting cells confers the ability to sup-
press “unwanted” T cells, particularly autoreactive ones
(14, 25), and thereby contributes to peripheral tolerance
against self-antigens. Indirect proof for the role of IDO in
suppression of alloreactive T cells was obtained by Munn et
al. (15) who showed that inhibition of IDO resulted in re-
jection of the fetus in pregnant mice. In the current series
of experiments, we present a model for studying the effect
of IDO on allogeneic T cells by transgenetically expressing
the IDO gene in human DCs and coincubating these cells
with allogeneic T cells. IDO-expressing DCs reduced tryp-
tophan, increased kynurenine, and (as expected) suppressed
the proliferation of allogeneic T cells.
Munn et al. (3, 14) found that IDO-expressing macro-
phages catabolize virtually the entire amount of tryp-
tophan in a cell culture system comparable to ours.
Although in the experiment presented herein IDO-
expressing DCs decreased the tryptophan concentration
from a mean of 25.73  M to a mean of 15.64  M, it
should be mentioned that variations down to unmeasurable
tryptophan concentrations were noted in other cell cul-
tures, a phenomenon obviously due to different activities of
the IDO gene. Such very low tryptophan concentrations
can impair T cell proliferation. However, we also noted T
cell suppression at measurable tryptophan concentrations,
provided that IDO was expressed in DCs. According to the
tryptophan titration curve, such “measurable” concentra-
tions are not low enough to impair T cell proliferation.
This latter observation argues against tryptophan deficiency
being the only factor responsible for suppressed T cell pro-
liferation in our cell cultures. For tryptophan deficiency as a
mechanism responsible for IDO-induced T cell suppression
in vivo, it must be postulated that concentrations  0.5–1
 M (14) are generated and maintained for a longer time in
certain microenvironments. Since plasma levels are in the
range of 50–100  M and never reach such low concentra-
tions, and since the diffusion of tryptophan into tissues evi-
dently is faster than the local degradation rate, this proposed
mechanism appears questionable (14, 22, 28).
Figure 9. Induction of cell death by tryptophan metab-
olites. Lymphocytes were stimulated with anti-CD3 in the
presence or absence (control) of active metabolites (1,501
 M kynurenine, 349  M 3-hydroxykynurenine, 510  M
3-hydroxyanthranilic acid) or a metabolite mixture
(kynurenine  plus 3-hydroxykynurenine  plus anthranilic
acid plus 3-hydroxyanthranilic acid plus quinolinic acid)(64
 M of each compound). After 3 d the cells were washed,
stained with anti-CD3-FITC antibody and 7-AAD. The
percentages of dead (7-AAD-positive) T cells was deter-
mined in FACScan™. A shows the lymphocyte gate. B–F
show the percentage of dead cells in the negative control
and after treatment with kynurenine, 3-hydroxyanthranilic
acid, 3-hydroxykynurenine, or metabolite mixture.
Figure 10. Time dependency of cytotoxicity and preferential killing of
activated T cells. T cells were separated from PBMCs using magnetic
beads and kept in culture (A) with anti-CD3 antibody or (B) without
anti-CD3 antibody, in the presence of a mixture of tryptophan metabo-
lites (kynurenine plus 3-hydroxykynurenine plus anthranilic acid plus
3-hydroxyanthranilic acid plus quinolinic acid) (concentrations: 0, 8, 16,
32  M for each compound). The percentage of dead cells (ordinate) was
measured every day (abscissa) by 7-AAD staining.454 IDO-induced T Cell Suppression Is Mediated by Tryptophan Metabolites
Surprisingly, in contrast to previous speculations (3), we
found that kynurenine suppresses the T cell response. In-
hibitory concentrations in the kynurenine titration experi-
ments were 157–553  M, which was strikingly higher than
the 12.5  M average concentration found in our cultures
of IDO-expressing DCs. Therefore, at the first glance,
kynurenine did not provide a plausible explanation for T
cell suppression by IDO-expressing DCs. However, it is
well known that besides kynurenine, IDO-induced degra-
dation of tryptophan results in additional catabolites. Con-
sequently, kynurenine does not act alone but in the pres-
ence of other metabolites. As shown by our experiments,
3-hydroxykynurenine and 3-hydroxyanthranilic acid are
also T cell suppressive and have an additive effect when
mixed with kynurenine. When 15  M kynurenine, a con-
centration which does not result in any T cell suppression
by itself, acts in concert with the same amounts of all other
metabolites (or 3-hydroxykynurenine and 3-hydroxyan-
thranilic acid only), the combined activity suppresses the T
cell response. It should also be mentioned that Grohmann
et al. (29) found considerably higher kynurenine concen-
trations in their IFN- –stimulated CD8   DC cultures
than those noted by us.
Of course, it is difficult to extrapolate from observations
in cell cultures to conditions in vivo. The question must be
posed, however, whether the inhibitory kynurenine con-
centrations found in our study are comparable to those
present in vivo. Normal serum kynurenine concentrations
in humans range from 1 to 3  M (22). This is far below the
inhibitory levels observed in our experiments, a finding
which is not surprising because under normal conditions
blood lymphocytes are not suppressed. Low blood levels,
however, do not exclude the existence of high levels of
kynurenine and its derivatives at defined sites in the body.
It is known that IDO production in tissues is limited to
certain cells (3). During pregnancy, for instance, IDO is ex-
pressed in the placenta and creates a site of local immuno-
suppression toward fetal tissue (15), although pregnant
women are not generally immunosuppressed and their se-
rum shows no change in kynurenine concentrations (28).
In one study, quinolinic acid, the terminal kynurenine me-
tabolite, was measured in the brain and blood of HIV-
infected patients. In brain, this metabolite was elevated
 300-fold. There were no significant correlations, how-
ever, between serum quinolinic acid levels and those in
cerebrospinal fluid or brain parenchyma (30). Evidently,
the serum does not necessarily reflect the concentrations at
the site of production. On the other hand, under certain
circumstances, kynurenine metabolites may dramatically
increase even in serum or urine. Cancer patients, for in-
stance, treated with IFN type I or type II, a cytokine which
induces IDO, have decreased serum tryptophan levels and
5–500-fold increased urinary kynurenine metabolite con-
centrations (31). Serum of AIDS patients showed 37-fold
higher quinolinic acid levels than serum of healthy controls
(30). In experiments in sheep, a species known to have
kynurenine concentrations comparable to those of humans,
tryptophan loading resulted in increased plasma concentra-
tion of 118   79.7  M kynurenine in pregnant as well as
in nonpregnant animals, whereas the concentration reached
an even higher peak (247.9   86.7  M) in fetal plasma
(32). These levels are in the range found to be suppressive
in our cell cultures and suggest that, under certain circum-
stances, T cell inhibitory kynurenine concentrations can be
achieved in vivo. Two important points must be consid-
ered when comparing in vitro kynurenine data with condi-
tions in vivo. First, our findings show that not only
kynurenine but other metabolites too, namely 3-hydroxy-
kynurenine and 3-hydroxyanthranilic acid, suppress the T
cell response. Interestingly, in studies concerning the neu-
rotoxic effect of tryptophan metabolites it was shown that
these compounds have an additive effect (33, 34). Our data
show that the T cell suppressive effect of several tryptophan
metabolites is additive in vitro. If this phenomenon also ap-
plies to conditions in vivo, relatively low kynurenine con-
centrations may be sufficient for suppression of the T cell
response. Second, in the same series of experiments dealing
with the toxic effect of tryptophan metabolites on nerve
cells, it was shown that the neurotoxic threshold of
3-hydroxykynurenine significantly decreased by prolonging
the exposure time (33). This finding fits with our observation
that the tryptophan metabolite mixture significantly in-
creases its cytotoxic effect on lymphocytes with every addi-
tional day of incubation. Under in vivo conditions, such as
Figure 11. Sensitivity of T, B, NK cells and DCs to
tryptophan metabolites. T, B, and NK cells were separated
from PBMCs and DCs were generated as described previ-
ously. The cells were incubated with a metabolite mixture
(kynurenine  plus 3-hydroxykynurenine  plus anthranilic
acid plus 3-hydroxyanthranilic acid plus quinolinic acid)
(concentrations: 0, 8, 16, 32  M for each metabolite). The
percentage of dead cells (ordinate) was measured by 7-AAD-
staining every day (abscissa).455 Terness et al.
AIDS, pregnancy, etc., the exposure time is obviously
longer than the duration of cell cultures used in the present
study and lower kynurenine concentrations might there-
fore be effective.
Our experiments indicate that the mechanism of T cell
suppression by kynurenine and some of its derivatives is cell
death. This explains the lack of restimulation of kynure-
nine-suppressed T cells. Interestingly, it was shown (35)
that macrophages, cells belonging to the IDO-expressing
subpopulation (14, 24, 25), can promote apoptosis of pe-
ripheral blood T cells. Moreover, treatment of DCs with
IFN-  increases their IDO activity and confers tolerogenic
properties apparently by initiating apoptosis of antigen-spe-
cific CD4 cells (27, 29, 36, 37). Our findings suggest that
the latter phenomenon is induced by kynurenine and its
derivatives, which means that these metabolites are possible
mediators of inhibitory DCs. As shown in our experiments
activated T cells are more susceptible to the cytotoxic ac-
tion of kynurenine metabolites than resting cells. At high
concentrations and longer exposure times, however, both
activated and nonactivated T cells die. Translated to alloge-
neic T cell stimulation, that means that donor-specific (ac-
tivated) clones die, whereas other (resting) clones are not
(or less) harmed when exposed to kynurenine derivatives.
Our restimulation experiments support this conclusion.
The observation concerning induction of T cell death by
kynurenine is in line with previous findings on the cyto-
toxic action of tryptophan metabolites on nerve cells.
These compounds are known to be increased in the central
nervous system in certain neurological diseases (33, 38, 39).
In a recent publication, Chiarugi et al. (33) describe the in-
duction of cell death in cortical neurons by 3-hydroxy-
kynurenine and quinolinic acid, whereby the former ap-
parently induces apoptosis and the latter necrosis.
Quinolinic acid has also been considered a possible media-
tor of neurological dysfunction in AIDS (40). Surprisingly,
our experiments show that only 3-hydroxykynurenine but
not quinolinic acid induces death of lymphocytes.
If functional in vivo, the mechanism delineated by our
findings might have far reaching consequences for immu-
noregulation and for the pathogenesis of certain diseases. As
already mentioned, IDO is involved in suppression of fetal
rejection and possibly in control of autoreactive T cells (3,
14, 15, 25). According to our observations, this suppression
might be mediated by tryptophan metabolites which result
from increased IDO activity. Consequently, high levels of
such metabolites in the fetal-maternal interface may consti-
tute a “gateway to inferno” which sentences to death all T
cells which pass through. Interestingly, our findings show
that not only T cells but also B and NK cells are affected.
In contrast, DCs, the cells which produce IDO, are resis-
tant to tryptophan metabolite cytotoxicity.
IDO-mediated suppression of the immune response ob-
tains special relevance in patients with HIV infection. Se-
lected strains of HIV-1 are capable of inducing IDO syn-
thesis with subsequent tryptophan metabolism in human
macrophages, a process apparently triggered by transient
production of IFN-  (41). In line with these observations
are clinical studies showing that the concentration of serum
kynurenine increases and that of tryptophan decreases with
immune stimulation in HIV-infected patients, resulting in a
high kynurenine/tryptophan ratio. Most importantly, this
ratio shows a reciprocal relationship to the CD4 count and
the stage of the disease (42). In the light of our findings, it is
tempting to speculate that tryptophan metabolites induce T
cell death and thus contribute to the immunsosuppression
observed in HIV-infected patients.
If the immune system “uses” IDO-producing DCs for
suppression of “unwanted” immune reactions, the same
strategy could be attempted for induction of tolerance in a
transplant setting. It has already been shown that donor
DC progenitors, when injected into the prospective trans-
plant recipient, prolong graft survival, conceivably by inac-
tivating donor-reactive T cells (43, 44). Our study points
out a way for deliberately generating “suppressive” donor
DCs which can be used for tolerance induction in trans-
plant recipients. Conceivable alternatives would be the di-
rect expression of the IDO-gene in the graft or the use of
tryptophan metabolites as immunosuppressive agents. The
latter therapeutic strategy is particularly interesting in the
light of our observation that tryptophan metabolites pref-
erentially kill activated T cells, the cells which mediate
graft rejection.
In conclusion, our experiments show that DCs which
transgenetically express IDO are able to lower the tryp-
tophan concentration, increase the kynurenine concentra-
tion, and suppress the allogeneic T cell response. The tryp-
tophan metabolites kynurenine, 3-hydroxykynurenine, and
3-hydroxyanthranilic acid inhibit T cell proliferation by a
time-dependent cytotoxic action, an effect which concerns
mainly activated T cells, but also B and NK cells.
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